流式细胞术
离体
直线(几何图形)
K562细胞
流量(数学)
细胞培养
体内
生物
分子生物学
数学
生物技术
遗传学
几何学
作者
Caroline Mitiká Watanabe,Caroline Ishihama Suzuki,Alessandro Marins-Dos-Santos,Thiago Pinheiro Arrais Aloia,Grace E. Lee,David N. Wald,Oswaldo Keith Okamoto,Julia T. Cottas de Azevedo,Juliana Aparecida Preto de Godoy,Fabio P S Santos,Ricardo Weinlich,Lucila Nassif Kerbauy,José Mauro Kutner,Raquel M. Alves‐Paiva,Nelson Hamerschlak
标识
DOI:10.1016/j.jtct.2024.07.004
摘要
Natural Killer (NK) cells play a crucial role in the immune system's response against cancer. However, the challenge of obtaining the required quantity of NK cells for effective therapeutic response necessitates the development of strategies for their ex vivo expansion. This study aimed to develop a novel feeder cell line, K562.Clone1, capable of promoting the ex vivo expansion of NK cells while preserving their cytotoxic potential. The K562 leukemic cell line was transduced with mbIL-21 and 4-1BBL proteins to generate K562.Clone1 cells. NK cells were then co-cultured with these feeder cells, and their expansion rate was monitored over 14 days. The cytotoxic potential of the expanded NK cells was evaluated against acute myeloid leukemia blasts and tumor cell lines of leukemia and glial origin. Statistical analysis was performed to determine the significance of the results. The K562.Clone1 co-cultured with peripheral NK showed a significant increase in cell count, with an approximately 94-fold expansion over 14 days. Expanded NK cells demonstrated cytotoxicity against the tested tumor cell lines, indicating the preservation of their cytotoxic characteristics. Additionally, the CD56, CD16, inhibitory KIRs, and activation receptors were conserved and present in a well-balanced manner. The study successfully developed a feeder cell line, K562.Clone1, that effectively promotes the expansion of NK cells ex vivo while maintaining their cytotoxic potential. This development could significantly contribute to the advancement of NK cell therapy, especially in Brazil.
科研通智能强力驱动
Strongly Powered by AbleSci AI